Evidence map›Paper›PMID 36590145›Full record

ArticleBreast care (Basel, Switzerland)2022

Lack of Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Early Breast Cancer.

Maria Del Rosario Sifón, Nicolas Marcolini, Maria Julia Barber, Ignacio Mclean, Manglio Rizzo, Sergio Rivero, Maria Victoria Costanzo, Adrian Nervo, Gabriel Crimi, Florencia Perazzo and 2 more

Abstract read
In one paragraph

Article in Breast care (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Harnessing hematological ratios: prognostic insights for breast cancer management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maria Del Rosario SifónClinical Oncology, Centro de Educación médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina.
Nicolas MarcoliniClinical Oncology, Hospital Universitario Austral (HUA), Buenos Aires, Argentina.
Maria Julia BarberBreast Surgery Unit, Hospital Universitario Austral (HUA), Buenos Aires, Argentina.
Ignacio McleanBreast Surgery Unit, Hospital Universitario Austral (HUA), Buenos Aires, Argentina.
Manglio RizzoClinical Oncology, Hospital Universitario Austral (HUA), Buenos Aires, Argentina.
Sergio RiveroClinical Oncology, Instituto Alexander Fleming (IAF), Buenos Aires, Argentina.
Maria Victoria CostanzoClinical Oncology, Instituto Alexander Fleming (IAF), Buenos Aires, Argentina.
Adrian NervoClinical Oncology, Instituto Alexander Fleming (IAF), Buenos Aires, Argentina.
Gabriel CrimiBreast Surgery Unit, Centro de Educación médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina.
Florencia PerazzoClinical Oncology, Centro de Educación médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina.
Estrella Mariel LevyCentro de Investigaciones Oncológicas, CIO-FUCA, Buenos Aires, Argentina.
Pablo MandóClinical Oncology, Centro de Educación médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast cancer is a highly heterogeneous disease with large differences in the risk of recurrence. An elevated neutrophil-to-lymphocyte ratio (NLR) is correlated with a poor prognosis in a variety of tumors, and although it is still controversial in breast cancer, there are multiple studies, including meta-analysis, suggesting this. The purpose of this study was to analyze the prognostic value of preoperative NLR in an Argentine population of patients with nonmetastatic breast cancer, not exposed to neoadjuvant treatment. Methods: Retrospective multicenter cohort study that includes patients over 18 years of age from three centers in the city and province of Buenos Aires who have had surgery for early breast cancer between January 1, 1999, and December 31, 2014. Based on the previous literature, a cutoff value of 2.0 was defined. Results: A total of 791 patients were eligible for the analysis. Median age was 55 years (IQR 45-65). Median NLR was 1.92 (IQR 1.50-2.56). The distribution of groups according to the 8th edition of the AJCC was 54.1% for stage I, 35.6% stage II, and 10.4% stage III. Among the different tumor phenotypes, 79.0% were HR+/HER2-, 11.4% were HR+ or-/HER2+, and 9.2% were HR-/HER2-. With a median follow-up of 5.3 years, 112 patients (14.2%) had disease recurrence. Stage III patients had a higher NLR than stage I and stage II patients ( Conclusion: We consider it is important to determine the efficacy of prognostic markers that are easily accessible and of simple, systematic application. However, NLR does not appear to be an independent prognostic factor for recurrence in our population. In this sense, we consider it is important to publish negative results in order to avoid publication bias.

Indexed as

Early breast cancerNeutrophil-to-lymphocyte ratioPrognostic factor

Identifiers

PMID36590145
PMCPMC9801394

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.